Literature DB >> 18786207

Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.

Manabu Tatokoro1, Satoru Kawakami, Junji Yonese, Yasuhisa Fujii, Yuhei Okubo, Shinya Yamamoto, Hideki Takeshita, Yoshinobu Komai, Yuichi Ishikawa, Iwao Fukui.   

Abstract

We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. From April 1995 to November 2004, four patients with adenocarcinoma of the urachus who developed metastases after definitive surgery were treated with the IFEP chemotherapy followed by consolidative radiotherapy or salvage surgery in good responders. During the median follow-up period of 26 months, three of the four patients responded to the regimen (75%). In one patient with pulmonary metastases, four cycles of the IFEP chemotherapy, followed by stereotactic consolidative radiotherapy resulted in a complete remission for more than 8 years. Two patients achieved partial remission after the IFEP chemotherapy. We have demonstrated the IFEP chemotherapy is one of the most effective chemotherapy regimens against metastatic adenocarcinoma of the urachus. A multimodal treatment strategy, even with curative intent, can be considered when a sufficient effect was obtained by the IFEP chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786207     DOI: 10.1111/j.1442-2042.2008.02113.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Combined modalities treatment of pulmonary metastasis from an urachal adenocarcinoma.

Authors:  Fabrice Piégay; Jean-François Mornex
Journal:  Rare Tumors       Date:  2013-07-20

2.  A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.

Authors:  Christine Elser; Joan Sweet; Sendhil K Cheran; Masoom A Haider; Michael Jewett; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  Clinical outcome of urachal cancer in Japanese patients.

Authors:  Tatsuro Hayashi; Takeshi Yuasa; Sho Uehara; Yasushi Inoue; Shinya Yamamoto; Hitoshi Masuda; Yasuhisa Fujii; Iwao Fukui; Junji Yonese
Journal:  Int J Clin Oncol       Date:  2015-07-03       Impact factor: 3.402

4.  Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy.

Authors:  Taku Naiki; Toshiki Etani; Aya Naiki-Ito; Kana Fujii; Ryosuke Ando; Keitaro Iida; Takashi Nagai; Yosuke Sugiyama; Motoo Nakagawa; Noriyasu Kawai; Takahiro Yasui
Journal:  Case Rep Oncol       Date:  2017-11-27

Review 5.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.